μMESH-Enabled Sustained Delivery of Molecular and Nanoformulated Drugs for Glioblastoma Treatment

Description

Modest tissue penetrance, nonuniform distribution, andsuboptimalrelease of drugs limit the potential of intracranial therapies againstglioblastoma. Here, a conformable polymeric implant, & mu;MESH,is realized by intercalating a micronetwork of 3 x 5 & mu;mpoly(lactic-co-glycolic acid) (PLGA) edges over arraysof 20 x 20 & mu;m polyvinyl alcohol (PVA) pillars for the sustaineddelivery of potent chemotherapeutic molecules, docetaxel (DTXL) andpaclitaxel (PTXL). Four different & mu;MESH configurations wereengineered by encapsulating DTXL or PTXL within the PLGA micronetworkand nanoformulated DTXL (nanoDTXL) or PTXL (nanoPTXL) within the PVAmicrolayer. All four & mu;MESH configurations provided sustaineddrug release for at least 150 days. However, while a burst releaseof up to 80% of nanoPTXL/nanoDTXL was documented within the first4 days, molecular DTXL and PTXL were released more slowly from & mu;MESH.Upon incubation with U87-MG cell spheroids, DTXL-& mu;MESH was associatedwith the lowest lethal drug dose, followed by nanoDTXL-& mu;MESH,PTXL-& mu;MESH, and nanoPTXL-& mu;MESH. In orthotopic models ofglioblastoma, & mu;MESH was peritumorally deposited at 15 days post-cellinoculation and tumor proliferation was monitored via bioluminescenceimaging. The overall animal survival increased from & SIM;30 daysof the untreated controls to 75 days for nanoPTXL-& mu;MESH and90 days for PTXL-& mu;MESH. For the DTXL groups, the overall survivalcould not be defined as 80% and 60% of the animals treated with DTXL-& mu;MESHand nanoDTXL-& mu;MESH were still alive at 90 days, respectively.These results suggest that the sustained delivery of potent drugsproperly encapsulated in conformable polymeric implants could haltthe proliferation of aggressive brain tumors.

Additional details